ANVS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.377

-12.4%

-0.370

+15.62%

-0.360

+12.5%

Estimates Revision

Stock Price

Go Up

+66.82%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 11.67 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

11.67

High

17.00

Current: 0.000

Low

8.00

Averages

11.67

High

17.00

H.C. Wainwright

Buy

downgrade

$12 -> $10

2025-09-03

Reason

H.C. Wainwright

Price Target

$12 -> $10

2025-09-03

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Annovis Bio to $10 from $12 and keeps a Buy rating on the shares. The firm says the company's buntanetap Alzheimer's disease pivotal trial remains in progress. It cites a lengthier time to potential approval for the target cut.

H.C. Wainwright

Buy

downgrade

$30 -> $12

2025-06-09

Reason

H.C. Wainwright

Price Target

$30 -> $12

2025-06-09

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Annovis Bio to $12 from $30 and keeps a Buy rating on the shares. The firm cites the impact of the most recent equity financing in February of this year, future potential equity issuances and the exercise of warrants for the target cut.

Canaccord

Sumant Kulkarni

Buy

downgrade

$26 -> $17

2025-05-15

Reason

Canaccord

Sumant Kulkarni

Price Target

$26 -> $17

2025-05-15

downgrade

Buy

Reason

Canaccord analyst Sumant Kulkarni lowered the firm's price target on Annovis Bio to $17 from $26 and keeps a Buy rating on the shares. The firm noted the released Q1 results which showed the company initiated its pivotal Phase 3 clinical trial for buntanetap for early Alzheimer's disease (AD). Previously the company had said earlier that it had reached alignment with the FDA on a pivotal trial with a 6-month endpoint focused on symptomatic benefit and an 18-month endpoint to address disease progression in early AD.

D. Boral Capital

Jason Kolbert

Strong Buy

Hold

Downgrades

n/a

2025-02-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

n/a

2025-02-10

Downgrades

Strong Buy

Hold

Reason

D. Boral Capital downgraded Annovis Bio to Hold from Buy without a price target after the company announced the pricing of an underwritten public offering of 5.25M shares. While the form anticipated a capital raise, the structure of the deal left it "disappointed." The company's ability to fully realize the second phase of this financing now depends on the stock reaching $5, the analyst tells investors in a research note. Boral says that instead of eliminating the financing overhang, the capital raise structure prolongs it, weighing on the stock and altering its investment thesis.

Valuation Metrics

The current forward P/E ratio for Annovis Bio Inc (ANVS.N) is -2.64, compared to its 5-year average forward P/E of -6.66. For a more detailed relative valuation and DCF analysis to assess Annovis Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.66

Current PE

-2.64

Overvalued PE

2.05

Undervalued PE

-15.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.95

Current EV/EBITDA

-2.10

Overvalued EV/EBITDA

0.27

Undervalued EV/EBITDA

-2.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ANVS News & Events

Events Timeline

No data

News

9.0

2025-12-19NASDAQ.COM

Annovis to Conduct 36-Month Extension Study for Further Assessment of Buntanetap in Parkinson's Disease

9.0

2025-12-18Newsfilter

Annovis Initiates 36-Month Study for Parkinson's Drug Buntanetap

1.0

2025-12-16Newsfilter

Annovis Bio to Host Webinar on Clinical Progress and Future Directions

People Also Watch

Frequently Asked Questions

What is Annovis Bio Inc (ANVS) stock price today?

The current price of ANVS is 3.67 USD — it has decreased -6.38 % in the last trading day.

What is Annovis Bio Inc (ANVS)'s business?

Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.

What is the price predicton of ANVS Stock?

What is Annovis Bio Inc (ANVS)'s revenue for the last quarter?

Annovis Bio Inc revenue for the last quarter amounts to -7.43M USD, increased 69.45 % YoY.

What is Annovis Bio Inc (ANVS)'s earnings per share (EPS) for the last quarter?

Annovis Bio Inc. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Annovis Bio Inc (ANVS)'s fundamentals?

The market is revising No Change the revenue expectations for ANVS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 66.82%.

How many employees does Annovis Bio Inc (ANVS). have?

Annovis Bio Inc (ANVS) has 8 emplpoyees as of January 10 2026.

What is Annovis Bio Inc (ANVS) market cap?

Today ANVS has the market capitalization of 97.27M USD.